Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense

Frias Boligan, Kayluz; Mesa, Circe; Fernandez, Luis Enrique; von Gunten, Stephan (2014). Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense. Cellular and molecular life sciences, 72(7), pp. 1231-1248. Springer 10.1007/s00018-014-1799-5

Preview

Text art_10.1007_s00018-014-1799-5.pdf - Published Version Available under License Publisher holds Copyright. Download (1MB) | Preview

Aberrant glycosylation is a key feature of malignant transformation and reflects epigenetic and genetic anomalies among the multitude of molecules involved in glycan biosynthesis. Although glycan biosynthesis is not template bound, altered tumor glycosylation is not random, but associated with common glycosylation patterns. Evidence suggests that acquisition of distinct glycosylation patterns evolves from a ‘microevolutionary’ process conferring advantages in terms of tumor growth, tumor dissemination, and immune escape. Such glycosylation modifications also involve xeno- and hypersialylation. Xeno-autoantigens such as Neu5Gc-gangliosides provide potential targets for immunotherapy. Hypersialylation may display ‘enhanced self’ to escape immunosurveillance and involves several not mutually exclusive inhibitory pathways that all rely on protein–glycan interactions. A better understanding of tumor ‘glycan codes’ as deciphered by lectins, such as siglecs, selectins, C-type lectins and galectins, may lead to novel treatment strategies, not only in cancer, but also in autoimmune disease or transplantation.

Interest & Impact

Downloads

132 since deposited on 19 Jan 2015
21 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item